Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
102.98
(
-1.39%
)
Bitcoin
70,222.80
(
0.46%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195897

Wednesday, 09/27/2017 11:47:05 AM

Wednesday, September 27, 2017 11:47:05 AM

Post# of 257262
MATN (f/k/a OXGN) -51% on phase-2/3 failure in ovarian cancer and termination of CA4P development (after all these years):

http://investor.mateon.com/releasedetail.cfm?ReleaseID=1041745

The drug MATN will now focus on, OXI4503, has been in development for 14 years! Check the date on this post: #msg-2166339.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now